Risk alert: FDA recalls ranitidine

April 1, 2020 Gracie Awalt

April 1, 2020

The Food and Drug Administration has recalled all prescription and over-the-counter ranitidine products due to contamination.

The FDA found that ranitidine, known over-the-counter as Zantac, contains the contaminant N-Nitrosodimethylamine (NDMA). According to the FDA, NDMA may cause cancer if it is exposed to above room temperature conditions. The FDA has not found NDMA in famotidine, cimetidine, esomeprazole, lansoprazole, or omeprazole.

The FDA recommends the following.

  • Patients taking OTC ranitidine should stop taking it and dispose of it properly.
  • Patients taking prescription ranitidine medication should speak with their health care professional discuss alternative medications.  
  • In light of the COVID-19 pandemic, do not take recalled medications to a drug take-back location. Instead, follow these drug disposal guidelines provided by the FDA.

Report adverse events or side effects to the FDA's MedWatch Safety Information and Adverse Event Reporting Program by doing one of the following:

Previous Article
How to psychologically evaluate patients before selection for surgery
How to psychologically evaluate patients before selection for surgery

Evaluating a patient’s mental health is an essential risk management consideration for plastic surgeons.

Next Article
TMB passes emergency rules enforcing ban on elective procedures
TMB passes emergency rules enforcing ban on elective procedures

Physicians could face license suspension for failure to follow governor’s COVID-19 orders